| Literature DB >> 26201864 |
Dinesh Bharti, Sharath Belame Shivakumar, Raghavendra Baregundi Subbarao, Gyu-Jin Rho1.
Abstract
In the present era of stem cell biology, various animals such as Mouse, Bovine, Rabbit and Porcine have been tested for the efficiency of their mesenchymal stem cells (MSCs before their actual use for stem cell based application in humans. Among them pigs have many similarities to humans in the form of organ size, physiology and their functioning, therefore they have been considered as a valuable model system for in vitro studies and preclinical assessments. Easy assessability, few ethical issues, successful MSC isolation from different origins like bone marrow, skin, umbilical cord blood, Wharton's jelly, endometrium, amniotic fluid and peripheral blood make porcine a good model for stem cell therapy. Porcine derived MSCs (pMSCs have shown greater in vitro differentiation and transdifferention potential towards mesenchymal lineages and specialized lineages such as cardiomyocytes, neurons, hepatocytes and pancreatic beta cells. Immunomodulatory and low immunogenic profiles as shown by autologous and heterologous MSCs proves them safe and appropriate models for xenotransplantation purposes. Furthermore, tissue engineered stem cell constructs can be of immense importance in relation to various osteochondral defects which are difficult to treat otherwise. Using pMSCs successful treatment of various disorders like Parkinson's disease, cardiac ischemia, hepatic failure, has been reported by many studies. Here, in this review we highlight current research findings in the area of porcine mesenchymal stem cells dealing with their isolation methods, differentiation ability, transplantation applications and their therapeutic potential towards various diseases.Entities:
Mesh:
Year: 2016 PMID: 26201864 PMCID: PMC5403966 DOI: 10.2174/1574888x10666150723145911
Source DB: PubMed Journal: Curr Stem Cell Res Ther ISSN: 1574-888X Impact factor: 3.828
CD markers expression and differentiation potential of porcine mesenchymal stem cells.
|
|
|
|
|
|
|---|---|---|---|---|
| Bone Marrow | CD44, CD29, CD90, CD105 | CD14, CD45 | Adipo, Osteo, Hepato | [ |
| Bone Marrow | CD29, CD105, | CD45 | Adipo, Osteo | [ |
| Bone Marrow | CD29, CD44 | CD45, CD31 | Adipo, Myocytes | [ |
| Bone Marrow | CD29, CD90, CD44, CD147, CD105 | CD45 | Osteo | [ |
| Bone Marrow | CD105, CD44 | CD34, CD45 | Adipo, Osteo | [ |
| Skin | CD29, CD44, CD90, | Osteo | [ | |
| Skin | CD44, CD29, CD90, Vimentin | SLA-DR | Neuronal | [ |
| Skin | CD29, CD9, CD44, CD105 | Neuronal, Adipo | [ | |
| Wharton’s Jelly | CD29, CD44, CD90 | CD45, CD49f, MHC CLASS 11, SLA-DR, PANCYTOKERATIN | Neuronal | [ |
| Umbilical cord blood | CD29, CD105, CD49b | CD133, CD45 | Adipo, Osteo, Chondro | [ |
| Endometrium | CD29, CD44, CD144, CD105, CD140b | CD34, CD45 | Adipo, Osteo | [ |
| Endometrium | CD29, CD44, CD90 | CD19, CD34, CD45 | Adipo, Osteo, Neuro | [ |
| Adipose tissue | CD29, CD44, CD90 | Adipo, Osteo, Chondro, neuronal | [ | |
| Adipose tissue | CD44, CD29, CD90, CD105 | CD14, CD45 | Adipo, Osteo, Hepato | [ |
| Adipose tissue | CD90, CD44 | CD45, CD31 | Adipo, Osteo, Chondro | [ |
| Adipose tissue | CD90, CD44, CD105 | CD34, CD45 | Hepato | [ |
| Aorta tunica media | CD90, CD73, CD105, CD56 | CD34, CD45 | Adipo, Osteo, Chondro | [ |
Therapeutic potential of porcine mesenchymal stem cells in various experimental disease models. SMCs: Synovial Mesenchymal cells, UCM: Umbilical Cord Matrix.
|
|
|
|
|
|
|---|---|---|---|---|
| Porcine BM-MSCs | Implantation of simvastatin treated BM-MSCs | Acute Myocardial infarction (Porcine) | Improved cardiac perfusion, reduced oxidative stress and proinflammatory cytokine expression, inhibition of apoptosis in periinfarct myocardium. | [ |
| Porcine BM-MSCs | Allogenic BM-MSCs/ 150 x106 cells/ml | Myocardial infarction | Higher ventricular GAP43-positive and sympathetic nerve density, higher tenascin expression and increased cardiac nerve sprouting magnitude. | [ |
| Porcine BM-MSCs | Allogenic BrdU pos and Y pos labelled male MSCs / 2.0 x 108 cells | Chronic ischemic | Restoration of cardiac function and perfusion along-with the formation of gap junctions followed by infarct scar reduction and neovascularization. | [ |
| Porcine BM-MSCs | Autologous Di-I-labeled BM-MSCs implantation by direct injection / 6 x 107 cells | Myocardial infarction | Robust MSCs engraftment, stable hemodynamic variables, attenuation of contractile dysfunction, maintenance of wall thickness | [ |
| Porcine BM-MSCs | Xenogeneic BM-MSCs injected directly into periinfarct heart zone / 1 x 10 6 80 PD cells | Acute Myocardial infarction (Mice) | Engrafted MSCs survival for at least 4 weeks, better capillarity in periinfarct zone, Functional improvement in heart, | [ |
| Porcine ASCs | Autologous ASCs / 50 x 106 cells | Cutaneous radiation syndrome (Porcine) | Ultimate wound healing in 80% grafted animals with complete epidermis recovery with favored lymphocyte infiltration in irradiated dermis. | [ |
| Porcine BM-MSCs | Allogenic BM-MSCs injected intradermally/ CM-Dil labelled/ 2.5/1.5/0.5 x 107 cells/ml | Skin regeneration (Porcine) | Increase in expanded skin area, thickened epidermis and thinned dermis with higher VEGF, bFGF, EGF and SDF gene expression. | [ |
| Porcine GFP-MSCs | Transplantation of IL-1Ra chitosan particles loaded MSCs/ 8 x 107 cells | Acute liver failure (Porcine) | Significant improvement in inflammation environment, liver function and hepatocyte proliferation, elevation in levels of HGF and VEGF. | [ |
| Porcine ASCs | Transplantation of BrdU labelled xenogeneic ADSCs/ 1x 108 cells | Acute-on-chronic liver failure (Rabbit) | Improved survival rate and liver function, normal hepatic trabecular architecture with moderate mononuclear infiltration, no tumor development. | [ |
| Porcine BM-MSCs | Implantation of autogenous tissue engineered undifferentiated BM-MSCs | Osteochondral defect | Smooth fully / partially repaired surfaces with better restoration of subchondral bone and lower pineda score. | [ |
| Porcine SMCs | SMSCs derived tissue engineered constructs (TEC)/ 4 x 105 cells/ml | Partial thickness chondral defect (Porcine) | Chondrogenic tissue like repair, exhibition natural cartilage like mechanical properties, absence of abnormal inflammation and necrosis. | [ |
| Porcine SMCs | Allogeneic SMSCs derived tissue engineered constructs (TEC) | Meniscal lesions (Porcine) | Defects filled with fibrous repair tissue showing good integration with adjacent host meniscal body, absence of any infection or abnormal inflammation. | [ |
| Porcine BM-MSCs | Autologous BM-MSCs / labelled with PKH-26 / 10 x 107 cells/ml | Endotoxin induced pulmonary hypertension and hypoxemia (Ex-vivo) (Porcine) | Reduction in endotoxin-induced pulmonary hypertension and hypoxemia, reduced lung edema, decrease in levels of IL-1β, TNF-α and IL-6. | [ |
| Porcine UCM-MSCs | Transplantation of eGFP engineered UCM-MSCs into rat brain / 150 cells | 6-OHDA lesioned rat brain (Rat) | No evidence of host immune response, differentiation into TH-positive cells with gradual increase in percentage | [ |
| Porcine UCM-MSCs | Xenogeneic PKH26-GL labelled UCM-MSCs transplanted into right substantia nigra / 104 cells/ul | Parkinson's disease (Mouse) | Engraftment and no host immune response, differentiation of cells into TH positive cells, improved basic motor behavior | [ |